UBC's Inventions and Licensing team (I&L) helps UBC researchers protect and advance high-potential discoveries. The team works with researchers to assess an invention's commercial potential, build a patenting strategy, evaluate spin-off potential, market to and negotiate with potential licensees, and finalize the agreements that move an invention to market. Each year, Inventions and Licensing assesses approximately 150 technology disclosures, files more than 300 patents, and manages a portfolio of over 2,800 patents.
This Staff Spotlight Q&A series is designed to introduce the people within the Inventions and Licensing team. Read all about Sandi Swa's expertise in immunology, good questions to ask when assessing the commercial potential of a new invention, and the UBC AVENGERS program Sandi is supporting.
Tell us a bit about yourself and the expertise you bring to the I&L team.
I’m a Technology Transfer Officer at Innovation UBC supporting researchers across the life sciences, medicine, dentistry and pharmaceutical sciences. I completed my PhD in immunology at the University of Edinburgh and got my start in technology transfer at Cancer Research UK. I first worked with UBC’s UILO in 2005 and have returned in several different roles over the years, working with both Sponsored Research and Inventions & Licensing Teams. This experience gives me a broad perspective on how managing research contracts and IP requires a team of people with deep expertise in their fields to come together during the innovation journey.
What information is most helpful when you’re assessing the commercial potential of a new invention?
A clear explanation of how the scientific discovery translates into an invention. We need to understand what problem the invention solves, how it could be used, the data supporting it, and what makes it different from current approaches. Researchers often have the best sense of the unmet need, who might use the invention, and through their extensive networks, which companies or potential partners are active in the area. Bringing that knowledge into the conversation helps us assess both the IP and commercial potential and work together on planning the best next steps.
What's a UBC spin-off or licensing success you've helped make happen that you're proud of?
Although this isn’t a spin-off or licensing success, I’m proud to be part of the team supporting UBC’s AVENGER program, through negotiation of NDAs with prospective industry partners. It’s a big, ambitious project that brings together researchers from across UBC, led by experienced innovators like Pieter Cullis and Anna Blakney. I’m really excited to see how their work in mRNA and lipid nanoparticle vaccine technology develops over the next few years.
Of the recent Express License updates, which do you think matters most for the researchers in your portfolio, and why?
For researchers with a life-science start-up, the updated flexibility around sublicensing is worth highlighting. Life-science spin-offs have a long product development pathway and often need development partners to help validate and de-risk their technology at the early stages. But the right partner for an early-stage technology may be a smaller biotech firm with specialized expertise rather than a larger company looking for something that’s already validated. Replacing the previous fixed market-cap requirement with an assessment of a partner’s financial and technical capabilities gives founders more freedom to work with the company best placed to move their technology forward.
Researchers with a disclosable invention, or questions about whether their work qualifies, are encouraged to reach out to Sandi or another member of the I&L team.
